Rapt Therapeutics, Inc.

As of May 11, 2023, Rapt Therapeutics, Inc. is considered overvalued with a valuation grade of "does not qualify" due to negative financial metrics, including a P/E ratio not applicable from losses, a Price to Book Value of 0.87, an EV to EBITDA of 0.19, and a troubling ROE of -65.69%, despite a recent stock surge of 622.33%.

As of June 17, 2025, Rapt Therapeutics, Inc. shows a mildly bullish trend supported by bullish MACD and Bollinger Bands, despite some short-term weakness indicated by the weekly RSI and mildly bearish daily moving averages.

As of March 2022, Rapt Therapeutics, Inc.'s management team includes Dr. Brian Wong as President and CEO, with independent directors Mr. Peter Svennilson, Dr. Michael Giordano, Dr. Mary Gray, Linda Kozick, and Mr. William Rieflin on the Board.

Rapt Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for oncology and inflammatory diseases. It has a market cap of $129.64 million and reported a net profit loss of $17 million as of March 2025.

As of Jun 18, Rapt Therapeutics, Inc. has a market capitalization of 129.64 million, with net sales of 0.00 million and a net profit of -116.50 million over the latest four quarters. As of December 2024, the company reported shareholder's funds of 189.90 million and total assets of 240.32 million.